Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

20 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Par Pharmaceuticals Articles

US FTC puts divestment conditions on Watson's acquisition of Actavis

16 October 2012

TPG completes $1.9 billion acquisition of Par Pharma

1 October 2012

USA FDA approves ANDAs for Plan B One-Step and Trandate

16 July 2012

Par Pharma acquires Handa's ANDA for generic Dexilant

23 April 2012

Par Pharma challenges FDA authority on off-label promotion

23 October 2011

US antitrust body OKs Teva's acquisition of Cephalon, but with divestments

10 October 2011

Intellipharmaceutics and Par Pharma expand Focalin accord

19 August 2011

Avanir sues Par and Actavis over Nuedexta patent infringement

12 August 2011

Par Pharma branded business faces setback, say Zacks analysts

17 July 2011

Lupin settles Lunesta patent litigation with Dainippon Sumitomo; Par Pharma starts shipping generic Rythmol and Lotrel

5 January 2011

Merck & Co settles US patent dispute over Zetia with Glenmark

11 May 2010

Showing 1-11 of 11 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • New study shows UCB's Neupro reduces NSBP in RLS patient
  • Encouraging results with Sangamo's SB-728-T in HIV treatment
  • Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
  • Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • New study shows UCB's Neupro reduces NSBP in RLS patient
  • Encouraging results with Sangamo's SB-728-T in HIV treatment
  • Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS